Benazepril Hydrochloride / HydrochlorothiazidePronouncation: (BEN-AZE-uh-pril HIGH-droe-CLOR-ide/high-droe-klor-oh-THIGH-uh-zide)
- Tablets 5 mg benazepril/6.25 mg hydrochlorothiazide
- Tablets 20 mg benazepril/25 mg hydrochlorothiazide
- Tablets 20 mg benazepril/12.5 mg hydrochlorothiazide
- Tablets 10 mg benazepril/12.5 mg hydrochlorothiazide
Mechanism of Action
Competitively inhibits angiotensin I-converting enzyme, resulting in the prevention of angiotensin I conversion to angiotensin II, a potent vasoconstrictor that stimulates aldosterone secretion. This action results in a decrease in sodium and fluid retention, increase in diuresis and a decrease in BP.Hydrochlorothiazide
Increases chloride, sodium, and water excretion by interfering with transport of sodium ions across renal tubular epithelium.
Indications and Usage
Treatment of hypertension. This fixed combination drug is not intended for the initial therapy of hypertension.
Anuric patients; patients hypersensitive to benazepril or any other ACE inhibitor; hydrochlorothiazide or other sulfonamide derivative.
Dosage and AdministrationAdults
PO Combination therapy with once-daily doses of 5 to 20 mg benazepril and 6.25 to 25 mg of hydrochlorothiazide in the morning and evening; take this medicine with or without food.
Store tablets at controlled room temperature (less than 86°F). Keep container tightly closed. Protect from moisture and light.
Drug InteractionsCholestyramine, colestipol
May impair the absorption of hydrochlorothiazide.Insulin
In diabetic patients, requirements of insulin may be increased, decreased, or unchanged.Lithium
Plasma levels of lithium may be elevated, increasing the risk of toxicity.Potassium supplements, potassium-sparing diuretics (eg, spironolactone)
Increased risk of hyperkalemia.Tubocurarine
Effects may be increased.
Laboratory Test Interactions
Hydrochlorothiazide may decrease serum protein-bound iodine levels without signs of thyroid disturbances.
Postural dizziness; hypotension; palpitations; syncope; tachycardia; peripheral vascular disorder; orthostatic hypotension.
Dizziness; headache; fatigue; somnolence; insomnia; nervousness; vertigo; lightheadedness; weakness; restlessness.
Rash; sweating; photosensitivity; purpura; urticarial rash; Stevens-Johnson syndrome.
Tinnitus; rhinitis; sinusitis; transient blurred vision; xanthopsia.
Nausea; vomiting; diarrhea; dyspepsia; anorexia; constipation; dry mouth; paresthesia; taste perversion; pancreatitis; sialadenitis; cramping; gastric irritation.
Impotence; urinary frequency; decreased libido.
Aplastic anemia; agranulocytosis; leukopenia; thrombocytopenia.
Intrahepatic cholestatic jaundice.
Gout; hyperglycemia; glucosuria.
Cough; upper respiratory infection; respiratory distress (including pneumonitis, pulmonary edema).
Hypertonia; angioedema (including edema of lips and face); flushing; arthralgia; myalgia; asthenia; pain (including chest and abdominal); back pain; flu-like syndrome; muscle spasm; necrotizing angiitis.
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, discontinue therapy as soon as possible.
Ensure that volume and/or salt depletion have been corrected before initiating therapy. Monitor and record BP and pulse. Should hypotension result, hold medication and notify health care provider. Monitor blood sugar in diabetic patient when drug is started or dose is changed. Report significant changes to health care provider.
Category D (second and third trimester); Category C (first trimester). ACE inhibitors (eg, benazepril) can cause injury or death to fetus if used during second or third trimester. When pregnancy is detected, discontinue as soon as possible.
Excreted in breast milk.
Safety and efficacy not established.
Use with caution.
Use with caution.
Use with extreme caution in patients with hereditary angioedema. Angioedema associated with laryngeal edema may be fatal.
Decreases in BP may occur, especially in salt- or volume-depleted patients as a result of dialysis, prolonged diuretic therapy, dietary salt restriction, diarrhea, or vomiting. Volume and salt depletion should be corrected before initiating therapy with benazepril/hydrochlorothiazide.
Has occurred with other ACE inhibitors.
Dehydration, electrolyte disturbances, hypotension.
- Advise patient to take prescribed dose once daily without regard to meals.
- Advise patient to try to take each dose at about the same time each day.
- Inform patient that drug controls, but does not cure, hypertension and to continue taking drug as prescribed even when BP is not elevated.
- Caution patient not to change the dose or stop taking unless advised by health care provider.
- Instruct patient to continue taking other BP medications as prescribed by health care provider.
- Instruct patient in BP and pulse measurement skills.
- Advise patient to monitor and record BP and pulse at home and to inform health care provider should abnormal measurements be noted. Also advise patient to take record of BP and pulse to each follow-up visit.
- Caution patient to avoid sudden position changes to prevent orthostatic hypotension.
- Instruct patient to lie or sit down if experiencing dizziness or lightheadedness when standing.
- Caution patient that inadequate fluid intake, excessive perspiration, diarrhea, or vomiting can lead to excessive fall in BP resulting in lightheadedness or fainting.
- Instruct diabetic patient to monitor blood glucose more frequently when drug is started or dose is changed and to inform health care provider of significant changes in readings.
- Caution patient to avoid unnecessary exposure to UV light (eg, sunlight, tanning booths) and to use sunscreen and wear protective clothing when exposed to UV light to avoid photosensitivity reaction.
- Emphasize to hypertensive patient importance of other modalities on BP: Weight control, regular exercise, smoking cessation, moderate intake of alcohol and salt.
- Caution patient to not take any potassium-containing salt substitutes or potassium supplements unless advised by health care provider.
- Instruct patient to stop taking drug and immediately report any of the following symptoms to health care provider: fainting, swelling of the face, lips, eyelids, or tongue, difficulty breathing.
- Instruct patient to inform health care provider if a persistent cough develops while taking this medication.